Understanding how to improve immune responses against hepatitis B virus
Hepatic Priming of CD4+ T cells Directs Effective Hepatitis B Virus Immunity
This study is looking at how kids and adults respond to the hepatitis B virus and aims to find ways to help the body fight off the virus better, with the hope of creating new treatments that can help people clear the virus and avoid serious liver problems.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11090325 on NIH RePORTER |
What this research studies
This research investigates the differences in immune responses to hepatitis B virus (HBV) between children and adults, focusing on how to enhance the body's ability to clear the virus. By using a mouse model that mimics human HBV infections and analyzing existing data from clinical trials, the study aims to identify key factors that influence the effectiveness of the immune response. The goal is to develop new therapies that can help patients achieve HBsAg seroclearance, which is crucial for preventing severe liver disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with chronic hepatitis B infection, particularly those who have not responded well to current treatments.
Not a fit: Patients who have cleared the hepatitis B virus or those with other liver diseases unrelated to HBV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enable patients to clear hepatitis B virus from their systems, reducing the risk of liver disease and cancer.
How similar studies have performed: Previous research has shown promise in understanding immune responses to hepatitis B, but this approach is innovative in its direct comparison of mouse and human data.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Carey, Nicholas Daniel — University of California, San Francisco
- Study coordinator: Carey, Nicholas Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.